93438-37-0
93438-37-0 structure
- Name: helospectin I
- Chemical Name: (4S)-5-[[(1S)-2-[[(1S)-2-[[(1S)-5-amino-1-[[(1S)-1-[[(1S)-1-[[(1S)-2-[[(1S)-5-amino-1-[[(1S)-1-[[(1S)-2-[[(1S)-1-[[(1S)-4-amino-1-[[(1S)-5-amino-1-[[(1S)-2-[[(1S)-1-[[(1S)-3-carboxy-1-[[(1S)-2-[[(1S,2S)-1-[[(1S)-1-[[2-[[(1S)-2-[[(1S)-2-[[(1S,2R)-1-[[(1S)-2-[(2S)-2-[[(1S)-1-[(2S)-2-[(2S)-2-[[(1S)-2-[[(1S)-1-carboxy-2-hydroxy-ethyl]amino]-1-(hydroxymethyl)-2-oxo-ethyl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carbonyl]-4-guanidino-butyl]carbamoyl]pyrrolidin-1-yl]-1-(hydroxymethyl)-2-oxo-ethyl]carbamoyl]-2-hydroxy-propyl]amino]-1-(hydroxymethyl)-2-oxo-ethyl]amino]-1-(hydroxymethyl)-2-oxo-ethyl]amino]-2-oxo-ethyl]carbamoyl]-3-methyl-butyl]carbamoyl]-2-methyl-butyl]amino]-1-(hydroxymethyl)-2-oxo-ethyl]carbamoyl]propyl]carbamoyl]-3-methyl-butyl]amino]-1-[(4-hydroxyphenyl)methyl]-2-oxo-ethyl]carbamoyl]pentyl]carbamoyl]-4-oxo-butyl]carbamoyl]-3-methyl-butyl]amino]-1-methyl-2-oxo-ethyl]carbamoyl]-3-methyl-butyl]carbamoyl]pentyl]amino]-1-methyl-2-oxo-ethyl]carbamoyl]-3-methyl-butyl]carbamoyl]-3-methyl-butyl]carbamoyl]pentyl]amino]-1-(hydroxymethyl)-2-oxo-ethyl]amino]-1-[(4-hydroxyphenyl)methyl]-2-oxo-ethyl]amino]-4-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-propanoyl]amino]-3-carboxy-propanoyl]amino]propanoyl]amino]-3-hydroxy-butanoyl]amino]-3-phenyl-propanoyl]amino]-3-hydroxy-butanoyl]amino]propanoyl]amino]-5-oxo-pentanoic acid
- CAS Number: 93438-37-0
- Molecular Formula: C183H293N47O59
- Molecular Weight:
- Catalog: Research Areas Cardiovascular Disease
- Create Date: 2021-09-12 19:23:40
- Modify Date: 2024-02-21 20:00:25
-
Helospectin I is a neuropeptide of the vasoactive intestinal peptide (VIP) family. Helospectin I has vasodilatory and antihypertensive activities, and decreases blood pressure. Helospectin I is originally isolated from the salivary gland venom of the lizard Heloderma suspectum[1][2].
| Name | (4S)-5-[[(1S)-2-[[(1S)-2-[[(1S)-5-amino-1-[[(1S)-1-[[(1S)-1-[[(1S)-2-[[(1S)-5-amino-1-[[(1S)-1-[[(1S)-2-[[(1S)-1-[[(1S)-4-amino-1-[[(1S)-5-amino-1-[[(1S)-2-[[(1S)-1-[[(1S)-3-carboxy-1-[[(1S)-2-[[(1S,2S)-1-[[(1S)-1-[[2-[[(1S)-2-[[(1S)-2-[[(1S,2R)-1-[[(1S)-2-[(2S)-2-[[(1S)-1-[(2S)-2-[(2S)-2-[[(1S)-2-[[(1S)-1-carboxy-2-hydroxy-ethyl]amino]-1-(hydroxymethyl)-2-oxo-ethyl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carbonyl]-4-guanidino-butyl]carbamoyl]pyrrolidin-1-yl]-1-(hydroxymethyl)-2-oxo-ethyl]carbamoyl]-2-hydroxy-propyl]amino]-1-(hydroxymethyl)-2-oxo-ethyl]amino]-1-(hydroxymethyl)-2-oxo-ethyl]amino]-2-oxo-ethyl]carbamoyl]-3-methyl-butyl]carbamoyl]-2-methyl-butyl]amino]-1-(hydroxymethyl)-2-oxo-ethyl]carbamoyl]propyl]carbamoyl]-3-methyl-butyl]amino]-1-[(4-hydroxyphenyl)methyl]-2-oxo-ethyl]carbamoyl]pentyl]carbamoyl]-4-oxo-butyl]carbamoyl]-3-methyl-butyl]amino]-1-methyl-2-oxo-ethyl]carbamoyl]-3-methyl-butyl]carbamoyl]pentyl]amino]-1-methyl-2-oxo-ethyl]carbamoyl]-3-methyl-butyl]carbamoyl]-3-methyl-butyl]carbamoyl]pentyl]amino]-1-(hydroxymethyl)-2-oxo-ethyl]amino]-1-[(4-hydroxyphenyl)methyl]-2-oxo-ethyl]amino]-4-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-propanoyl]amino]-3-carboxy-propanoyl]amino]propanoyl]amino]-3-hydroxy-butanoyl]amino]-3-phenyl-propanoyl]amino]-3-hydroxy-butanoyl]amino]propanoyl]amino]-5-oxo-pentanoic acid |
|---|
| Description | Helospectin I is a neuropeptide of the vasoactive intestinal peptide (VIP) family. Helospectin I has vasodilatory and antihypertensive activities, and decreases blood pressure. Helospectin I is originally isolated from the salivary gland venom of the lizard Heloderma suspectum[1][2]. |
|---|---|
| Related Catalog | |
| Target |
Vasoactive intestinal peptide (VIP)[1] |
| In Vitro | Helospectin I (suffusion at 0.1 nM, in bicarbonate buffer for 30 min) evokes significant, sustained and similar vasodilation in the intact hamster cheek pouch[1]. Helospectin I relaxes the Phenylephrine-contracted rat femoral arteries with pEC50 of 6.82[2]. Helospectin I (0.1 nM-1 μM) inhibits the binding of 125I-labeled VIP and 125I-secretin to dispersed chief cells[4]. |
| In Vivo | Helospectin I (0.03-2 nmol/kg, 100 μL of infusion at the left jugular vein) reduces blood pressure in rats[2]. Helospectin I (0.1-0.8 nmol /kg, i.v.) increases plasma levels of glucagon in mice[3]. Animal Model: SD rats[2] Dosage: 0.03, 0.3, 1, 2 nM/kg Administration: 100 μL of infusion at the left jugular vein, followed by washing the catheter with 100 μL saline. Result: Reduced the blood pressure, but was less effective than vasoactive intestinal peptide (VIP) in the low dose range. Animal Model: Mice[3] Dosage: 0.1, 0.2, 0.4, 0.8 nM /kg Administration: Intravenous injection (i.v.) Result: Markedly stimulated glucagon secretion, and had no direct action on insulin secretion. |
| References |
| Molecular Formula | C183H293N47O59 |
|---|